Shilpa Medicare share news and announcements
NSE: SHILPAMEDBSE: 530549Pharmaceuticals & BiotechnologySmall Cap
Last close ₹864.30up ₹3.50 (0.41%)BSE ₹862.80
Share price at the NSE close on 23 Oct 2026. Previous close ₹860.80.
52-week range of traded prices to 23 Oct 2026
₹259.50Low, 27 Jan 2026₹1,095.00High, 1 Oct 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹16,904 Cr637th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 5 Aug 2026
- 56.9
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹30 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 63.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 22 May 2026
- 6.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.07%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 5 Aug 2026
- 12.0%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹30 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 10.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 10.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 22 May 2026
- 0.25
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 9,55,72541.8% delivered
Shilpa Medicare share news and announcements
754 announcements, routine notices left out, newest first. Page 14 of 16.
Mar 2015
Feb 2015
2 Feb · Board meeting
Inter alia, to consider the un-audited financial results for the quarter ended December 31, 2014.
Nov 2014
3 Nov · Board meeting
To consider the un-audited financial results for the quarter ended September 30, 2014.
Sep 2014
Aug 2014
26 Aug · Meeting
Register of Members and Share Transfer Books of the Company shall remain closed from September 13, 2014 to September 19, 2014 for the purpose of payment of Dividend for the financial year 2013-14 and Annual General Meeting to be held on September 20, 2014.4 Aug · Updates
Trading Window shall remain closed from August 8, 2014 to August 16, 2014, both days inclusive, for the following categories (including dependents)- Directors, Designated Employees, Auditors, as per the code of conduct for prevention of Insider Trading regulations, framed and adopted in accordance with SEBI (Prohibition of Insider Trading) Regulations, 1992.
May 2014
29 May · Dividend
Board of Directors of the Company at its meeting held on May 29, 2014 has recommended a dividend of Re.1/- (One) per equity share of Rs.2/- (Two) each (i.e. 50%) for the financial year 2013-14.12 May · Disclosure of Voting Pattern - Clause 35A
Apr 2014
11 Apr · Board meeting
Feb 2014
5 Feb · Updates
Pursuant to the provisions of code of conduct for prevention of insider trading Regulations, framed and adopted in accordance with SEBI (Prohibition of insider trading) Regulations, 1992, the Trading will remain closed from February 03, 2014 to February 11, 2014, both days inclusive, for the following categories (including dependents): (a) Directors (b) Designated Employees (c) Auditors.
Jan 2014
Nov 2013
Oct 2013
31 Oct · Board meeting
To consider the Un-audited Financial Results of the Company for the quarter ended September 30, 2013.
Aug 2013
5 Aug · Board meeting
To consider the un-audited financial results of the Company for quarter ended June 30, 2013.
Jul 2013
4 Jul · Corporate action
Company has fixed Book Closure from July 18, 2013 to July 19, 2013 for the purpose of a) Bonus Issue; b) AGM and c) Payment of Dividend for the financial year 2012-13.
Jun 2013
27 Jun · Updates
Shilpa has signed an agreement with The United Nations-backed Medicines Patent Pool (MPP) and Gilead Sciences to increase access to medicines for HIV/AIDS treatment. Shilpa Medicare Limited (SML) will now be able to produce five key HIV medicines i.e. Tenofovir, Emtricitabine, Cobicistat, Elvitegravir and a combination of the four, known as "the Quad" for sale in over 100 countries, depending on the medicine. SML will be able to produce similar version of above drugs at a lower price once technology is transferred. These products will be marketed through Reva Pharma an associate Company of SML With above development SML will be able to utilize its expanded capacities and expect to improve working . It will also be able to expand its business in various countries.12 Jun · Updates
The Company's State of art facility at Pharma Park Jadcherla (SEZ), near Mahaboobnagar (AP) for undertaking 'Contract Research & Forward Integration i.e. Own Formulation' (Manufacturing of Oral & Injectible (Onco Products) has started functioning partially. Facility for manufacture of Formulation section will commence commercial production in stages after successful completion of trial production/stability tests etc. which is underway. The Company had visualized Contract Research as one of the thrust area few years back. It invested in creating Research & Development Centre's at two places. Such investment has started yielding results. It expects that this will grow in time to come and would become an important source of income, besides inventing new/improved products for the Company
May 2013
29 May · Dividend
Board of Directors of the Company at its meeting held on May 29, 2013 has recommended a dividend of 65% i.e. Re. 1.30 (Rupee One & Thirty Paise Only) per equity share of Rs. 2/- each for the financial year 2012-13.29 May · Corporate action
Board of Directors of the Company at its meeting held on May 29, 2013 has decided to recommend to issue Bonus Shares in the ratio of 1 (One) for every 2 (Two) existing Shares held.20 May · Board meeting
Inter alia, to consider the following items:(1) To take on record the Audited Financial Results for the quarter and year ended March 31, 2013.(2) To consider the payment of dividend for the Financial year ended March 31, 2013.
Feb 2013
4 Feb · Board meeting
To consider the Unaudited financial Results of the Company for the quarter ended December 31, 2012.
Dec 2012
20 Dec · Updates
Vide letter dated December 19, 2012 that the "Company has been conferred First Prize of the National Energy Conservation Award-2012 in the Drugs & Pharmaceutical Sector from Ministry of Power, New Delhi".
Nov 2012
Oct 2012
30 Oct · Board meeting
To consider the Un-audited Financial Results of the Company for the quarter ended September 30, 2012.1 Oct · Updates
Hon'ble High Court of Andhra Pradesh has approved the scheme of amalgamation of Raichem Life Sciences Private Limited with Company with effect from April 01, 2011 (Appointed Date). A copy of Certified Copy of Order of Hon'ble High Court, which has been submitted to the Registrar of Companies. Further, the Board of Directors has taken the said order on record on September 27, 2012 and passed a resolution to merge the accounts of Raichem Life Sciences Private Limited w.e.f. April 01, 2011 (being Appointed Date) and file necessary returns, applications, forms and other documents with the respective authorities and to do all the needful to give effect to the said merger.
Aug 2012
30 Aug · Corporate action
Register of Members and Share Transfer Books of the Company will be closed from September 19, 2012 to September 22, 2012 (both days inclusive) for the purpose of AGM and payment of Dividend for the year 2011-12.